a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance ofits IND for TST005 from US ...
3.Faivre, S. et al. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver International 39, 1468–1477 (2019). 4.A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination...
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma PLoS One, 9 (3) (2014), p. e90353 CrossrefView in ScopusGoogle Scholar 56 J.P. Stevenson, H.L. Kindler...
Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposition of extracellular matrix. This study evaluated the efficacy and safety of the anti-PD-L1/TGF-β antibody ...
when, how and how much therapy would be beneficial or how much toxicity will be induced by chronically administered therapy. However, daily administration of a high dose of neutralizing TGF-β antibody in adult mice for 12 weeks and a lifetime exposure to soluble TβRII (sTβRII) in ...
Careful clinical trial design and comprehensive patient monitoring will be essential for successful translation of these preclinical findings. Conclusion Our study provides compelling evidence for the therapeutic efficacy of combining RT with YM101 (a bispecific antibody that targets TGF-β and PD-L1) ...
267In a phase 2 clinical trial, the TGFβ-blocking antibody fresolimumab (GC1008) was combined with focal irradiation for the treatment of metastatic breast cancer, and it was found to prolong median overall survival and demonstrated a favorable systemic immune response.268,269In addition, freso...
clinical benefit, probably due to breakdown of the blood brain barrier in this neoplastic tissue [106]. Results to date have provided evidence that Fresolimumab is well tolerated and is not associated with irreversible, life-threatening complications. It indicates that antibody targeting TGF-β may...
and primary sclerosing cholangitis, a small-molecule inhibitor of avβ1 in a phase 1 trial for liver fibrosis in the setting of non-alcoholic steatohepatitis, and a humanized monoclonal antibody targeting αvβ8 in a phase 1 study for enhancing responses to immune checkpoint inhibition in cancer...
when, how and how much therapy would be beneficial or how much toxicity will be induced by chronically administered therapy. However, daily administration of a high dose of neutralizing TGF-β antibody in adult mice for 12 weeks and a lifetime exposure to soluble TβRII (sTβRII) in ...